U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07094048) titled 'Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager' on July 11.

Brief Summary: Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant conce...